{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:15:14Z","timestamp":1782882914661,"version":"3.54.5"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,10,8]],"date-time":"2004-10-08T00:00:00Z","timestamp":1097193600000},"content-version":"vor","delay-in-days":4756,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[1991,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti\u2014acetylcholine receptor antibodies cannot be detected by standard radioimmunoassay in 10 to 15% of patients with generalized myasthenia gravis (seronegative myasthenia gravis). We investigated the effect of seronegative myasthenia gravis plasma on <jats:sup>22<\/jats:sup>Na<jats:sup>+<\/jats:sup> flux through acetylcholine receptors and voltage\u2010gated sodium channels in the human rhabdomyosarcoma cell line, TE671. Fourteen of 19 seronegative MG plasmas inhibited acetylcholine receptor <jats:sup>22<\/jats:sup>Na<jats:sup>+<\/jats:sup> flux; none inhibited voltage\u2010gated sodium channel flux. The inhibitory activity was found in the IgG\u2010depleted fraction, and copurified with IgM after gel\u2010filtration chromatography. Inhibitory activity was absent from the plasma of 8 healthy control subjects and of 6 patients with the Lambert\u2010Eaton myasthenic syndrome, but was present in the IgG\u2010depleted plasma fraction of 4 of 6 seropositive patients with myasthenia gravis and all 5 patients with demyelinating polyneuropathy. We conclude that a low\u2010affinity serum factor, probably an IgM antibody, found in a high proportion in patients with seronegative and those with seropositive myasthenia gravis may contribute to the muscle weakness in myasthenia gravis, but its role in these and other neuroimmunological disorders requires further investigation.<\/jats:p>","DOI":"10.1002\/ana.410300407","type":"journal-article","created":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T12:05:46Z","timestamp":1104581146000},"page":"550-557","source":"Crossref","is-referenced-by-count":70,"title":["Seronegative myasthenia gravis: A plasma factor inhibiting agonist\u2010induced acetylcholine receptor function copurifies with IgM"],"prefix":"10.1002","volume":"30","author":[{"given":"Takeshi","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Newsom\u2010Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.26.11.1054"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.48.12.1246"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.663610"},{"key":"e_1_2_1_5_2","first-page":"105","article-title":"Ultrastructural localisation of the terminal and lytic 9th complement component C9 at the motor endplate in myasthenia gravis","volume":"128","author":"Sahashi K","year":"1982","journal-title":"Immunol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1980.60.3.756"},{"key":"e_1_2_1_7_2","first-page":"1","article-title":"Myasthenia gravis: biology and treatment","volume":"505","year":"1987","journal-title":"Ann NY Aca. Sci"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(83)90096-5"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.4.514"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.61.718.725"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0140-6736(86)92259-2","article-title":"Myasthenia gravis without acetylcholine receptor antibody: a distinct disease entity","volume":"1","author":"Mossman S","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/337311c0"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(88)90044-6"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1523\/JNEUROSCI.09-03-01082.1989","article-title":"A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671","volume":"9","author":"Luther MA","year":"1989","journal-title":"Neurosci"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(88)90043-4"},{"key":"e_1_2_1_16_2","first-page":"269","article-title":"\u03b1\u2010Bungarotoxin and antiacetylcholine receptor antibody binding to the human acetylcholine receptor","volume":"3","author":"Vincent A","year":"1979","journal-title":"Ad Cytopharmacol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1016\/S0021-9258(19)75273-9","article-title":"Activation of the action potential Na+ ionophore by neurotoxins: an allosteric model","volume":"252","author":"Catterall WA","year":"1977","journal-title":"J Bio Chem"},{"key":"e_1_2_1_18_2","first-page":"378","article-title":"Greatly increased autoantibody production in myasthenia gravis by thymocyte suspensions prepared with proteolytic enzymes","volume":"54","author":"Willcox HNA","year":"1983","journal-title":"Clin Ex Immunol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.8.1057"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.8.1329"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1976.tb47693.x"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410100506"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.41.5.394"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270314"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410220614"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.10.1359"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880080311"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.410300407","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.410300407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T03:04:56Z","timestamp":1698030296000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.410300407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1991,10]]}},"alternative-id":["10.1002\/ana.410300407"],"URL":"https:\/\/doi.org\/10.1002\/ana.410300407","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,10]]}}}